Clinical Management Support: Known Interference Between Hemlibra® (emicizumab Injection) And Lab Assays Used To Diagnose Coagulopathy / Dic Caused By Covid-19 Infection

Hemlibra (emicizumab injection), a blood clotting medication, can interfere with certain laboratory tests used to diagnose blood clotting disorders and DIC (a serious clotting condition) in COVID-19 patients. This interference means the test results may not accurately reflect a patient's actual condition. The product is distributed across Canada.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2020-04-17

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/a8373275-2274-474c-9a61-5e9504da0be2